NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

pharmafile | January 27, 2020 | News story | Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda 

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda (liraglutide) for the weight management in obese or overweight patients.

The recommendation would have covered the use of Saxenda when taken alongside a reduced-calorie diet and increased physical activity

Trial data submitted in support of recommendation demonstrated that the drug, in combination with these lifestyle changes, was more effective than these measures alone in weight loss and delaying the development of type 2 diabetes. However, NICE argued that the long-term relevance of these data are in question, particularly with regard to its benefit on cardiovascular disease risk.

In terms of cost-effectiveness, NICE noted that Novo Nordisk included data on high-risk from obesity-related adverse events – adults with a BMI of over 35kg/m2 with pre-diabetes and a high-risk of cardiovascular disease – but that it did not include compelling data on the wider patient population covered by this new indication.

As a result, the institute could not reach an accurate cost-effectiveness estimate, noting that the ultimate estimate could come in at a rate much higher than the NHS is able to pay.

Obesity has now become a major health concern in England, affecting just over one in four of the adult population. Despite this rejection, NICE currently recommends Saxenda for the treatment of type 2diabetes.

Matt Fellows

Related Content


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content